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Characterization of Definitive
Lymphohematopoietic Stem Cells
in the Day 9 Murine Yolk Sac
Mervin C. Yoder,*²³‖ Kelly Hiatt,*² support to a model proposed thirty years ago that mi-
grating HSC from the extraembryonic yolk sac seed theParmesh Dutt,*² Pinku Mukherjee,*²
David M. Bodine,§ and Donald Orlic§ developing liver and establish hepatic hematopoiesis
(Moore and Owen, 1967; Moore and Metcalf, 1970).*Herman B Wells Center for Pediatric Research
²Department of Pediatrics Isolation and characterization of the yolk sac cells
with long-term repopulating ability would permit a more³Department of Biochemistry and Molecular Biology
Indiana University School of Medicine critical comparison with the biology of HSC arising at
other sites of hematopoiesis throughout murine ontog-Indianapolis, Indiana 46202
§Laboratory of Gene Transfer eny. While day 11 yolk sac HSC are known to express
the cell surface antigen AA4.1 and bind wheat germNational Center for Human Genome Research
Bethesda, Maryland 20892 agglutinin (WGA) (Huang and Auerbach, 1993; Lu et al.,
1996), the phenotype of HSC isolated from day 9 em-
bryos has not been determined. Because the sialomucin
CD34 is expressed on hematopoietic and endothelialSummary
cells throughout murine ontogeny (Krause et al., 1994;
Ziegler et al., 1994; Young et al., 1995; Morel et al., 1996;The site of origin of lymphohematopoietic stem cells
Sanchez et al., 1996; Marcos et al., 1997), we analyzed(HSC) that initiate definitive blood cell production in
CD34 expression on yolk sac hematopoietic cells iso-the murine fetal liver is controversial. Contrary to re-
lated from day 9±11 embryos to determine if this cellports that the preliver yolk sac does not contain defini-
surface antigen could be used to isolate and character-tive HSC, we observed that CD341 day 9 yolk sac cells
ize yolk sac HSC.repopulated multiple blood cell lineages in newborn
We report that yolk sac cells express the CD34 antigenhosts for at least 1 year. Furthermore, 100 CD341c-
and that hematopoietic cells with high expression ofKit1 day 9 yolk sac or para-aortic splanchnopleura
this molecule are enriched in high proliferative potential-(P-Sp) cells, known to give rise to embryonic HSC,
colony forming cells (HPP-CFC) and myeloid and ery-similarly repopulated hematopoiesis in recipient hosts.
throid colony forming cells. In addition to CD34 expres-Surprisingly, 37-fold more CD341c-Kit1 cells reside
sion, day 9 yolk sac cells coexpressed some but not allin the day 9 yolk sac than in the P-Sp. In sum, defini-
of the cell surface markers typically identified on thetive HSC are coexistent, but not equal in number, in the
surface of fetal liver and adult bone marrow HSC. Never-murine yolk sac and P-Sp prior to fetal liver col-
theless, CD341 yolk sac cells, isolated as early as day 9,onization.
repopulated erythroid, lymphoid, and myeloid lineages
long-term upon transplantation into primary newbornIntroduction
and secondary adult recipient animals. Finally, the in
vivo repopulating ability of CD341c-Kit1 day 9 yolk sacSince the yolk sac is the first site of hematopoiesis
HSC was compared to CD341c-Kit1 HSC isolated fromduring murine ontogeny, it is intuitive that the yolk sac
day 9 para-aortic splanchnopleura (P-Sp) cells; a regionis the first site of HSC development. However, this is
of the developing day 9 embryo known to give rise toa controversial issue in developmental hematopoiesis
definitive HSC (Cumano et al., 1996). CD341c-Kit1 day(Tavassoli, 1991; Dzierzak and Medvinsky, 1995; Zon,
9 pc yolk sac and P-Sp cells repopulated multiple blood1995; Peault, 1996). Recent, elegant studies have clearly
cell lineages in conditioned newborn recipients equiva-demonstrated that when using a conditioned adult
lently. These data indicate that HSC with the capacitymouse as a hematopoietic transplant recipient, defini-
to contribute to definitive hematopoiesis are present intive HSC activity is first detectable in the aorta-gonad-
the yolk sac and P-Sp of murine embryos soon aftermesonephros (AGM) region of the embryo at day 10,
establishment of the systemic circulation and beforefollowed by the liver and yolk sac on day 11 (Muller et
fetal liver hematopoiesis commences. HSC from eachal., 1994; Medvinsky and Dzierzak, 1996). These results
site may colonize the fetal liver to give rise to the HSCsupport a model whereby the first definitive HSC arise
that sustain life-long hematopoiesis.in the AGM and migrate to the fetal liver to establish
definitive hepatic hematopoiesis (Dzierzak and Medvin-
sky, 1995). In the same model, yolk sac hematopoietic
Resultsprecursors do not possess the capacity to contribute to
definitive hematopoiesis. In contrast, when conditioned
Phenotypic Analysis of Hematopoietic Cellsnewborn or embryonic mice are utilized as hematopoi-
at Different Stages of Murine Ontogenyetic transplant recipients, HSC contributing to definitive
Flow cytometric analysis for expression of the CD34hematopoiesis can be detected as early as day 8 or 9
cell-surface sialomucin on hematopoietic cells was con-in the murine yolk sac (Weissman et al., 1978; Yoder
ducted using cell populations isolated from the day 9±11and Hiatt, 1997; Yoder et al., 1997). These results lend
embryonic yolk sac, day 10±12 fetal liver, and adult bone
marrow. In general, the highest cell-surface CD34 ex-
pression was observed on cells isolated from day 9 yolk‖ To whom correspondence should be addressed.
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Figure 2. Analysis of Yolk Sac Hematopoietic Cell Surface Expres-
sion of a Variety of Markers for Adult Bone Marrow and Yolk Sac
Cell Populations
Dual fluorescence analysis of day 9 yolk sac cells for surface expres-
sion of several antigens is depicted in these FACS dot plots. The
percentages indicated are representative of 1 of 3 experiments.
Figure 1. CD34 Expression Is Highest in Cells Isolated from the Day
9 Yolk Sac but Is Present in Each Site of Hematopoiesis throughout
day 12 fetal liver, the estimated total number was con-Ontogeny
siderably greater in adult bone marrow (Table 1).
Pooled single-cell suspensions were stained with an isotype control
Murine adult bone marrow HSC express numerousor a CD34 monoclonal antibody. The isotype control±labeled cells
cell surface molecules including Sca-1, c-Kit, CD34,are depicted in the open histogram and the CD34-labeled cells in
the shaded histogram. The percentages indicated for the yolk sac CD38, CD43, CD44, H-2K, and Thy-1 and do not express
cells reflect cells with high and intermediate labeling, while the fetal antigens expressed by lineage-committed cells includ-
liver and adult bone marrow percentages reflect cells considered ing CD4, CD8, Gr-1, B220, Mac-1, and Ter-119 (Orlic et
positive. Percentages listed are for 1 representative experiment with al., 1993; Moore et al., 1994; Spangrude, 1994; Morrison
corresponding mean 6 SD values for 3±5 experiments depicted in
et al., 1995b; Ogata et al., 1995; Spangrude et al., 1995;Table 1.
Trevisan and Iscove, 1995; Palacios et al., 1996; Randall
et al., 1996). While fetal liver HSC express AA4.1, this
marker is not expressed by quiescent adult marrow HSCsacs (Figure 1). Three populations of cells with differing
levels of CD34 expression (CD34hi, CD34lo, CD34neg) (Orlic et al., 1993). Day 9 yolk sac cells were labeled
with monoclonal antibodies directed against many ofcould be identified in cells isolated from day 9±11 yolk
sacs. The population of CD34hi-expressing cells in the the above antigens plus CD34 antibody and analyzed
by FACS. A subset of CD341 cells coexpressed c-Kit,day 9 yolk sac was greatly diminished in frequency by
day 11. In contrast to yolk sac cells, day 10±12 fetal liver CD38, CD44, and Mac-1 (Figure 2), although these anti-
gens were also expressed on CD342 day 9 yolk sacand adult bone marrow cells could only be resolved into
CD34lo and CD34neg populations (Figure 1). A significant cells (Figure 2). The adult marrow HSC marker Sca-1
was not expressed on either CD341 or CD342 day 9increase in the total number of CD341 cells was ob-
served from days 9 to 11 in the yolk sac and from days yolk sac cells (Figure 2). Other antigens that were coex-
pressed with CD34 by day 9 yolk sac cells included10 to 12 in the fetal liver (Table 1). While the percentage
of CD341 cells was lower in the bone marrow than in AA4.1 (6.2%), TER119 (11.6%), and CD24 (89.0%), but
Table 1. Estimated Number of CD341 Cells Present in Various Tissues throughout Murine Ontogeny
Cell Source % CD341 Cells Total Cells/Organ Total CD341 Cells/Organ
Day 9 YS 21 6 4 3.5 6 0.8 3 104 0.7 3 104
Day 10 YS 19 6 6 1.5 6 0.1 3 105 0.3 3 105
Day 11 YS 13 6 3 3.6 6 0.1 3 105 0.5 3 105
Day 10 FL 5a 1.8 6 0.4 3 104 0.1 3 104
Day 11 FL 4 6 1 4.1 6 0.7 3 104b 0.2 3 104
Day 12 FL 17 6 3 2.0 6 0.9 3 105b 0.3 3 105
Adult BM 8 6 3 2.4 3 108c 0.2 3 108
Day 9 P-Sp 12 6 4 4.6 6 0.1 3 103 0.6 3 103
Yolk sac (YS), fetal liver (FL), adult bone marrow (BM), and P-Sp cells were isolated and viable cells manually counted following trypan blue
staining. The % CD341 cell data represents the mean 6 SD results from 3±5 experiments (6±20 pooled embryos/experiment) with representative
data indicated in Figure 1. Total CD341 cell estimates per organ were derived by multiplying the mean % CD341 cell value 3 the mean total
cells/organ value.
a Data from one experiment.
b Adherent cell±depleted fetal liver cells isolated and thus an underestimate of total cell number.
c Number of bone marrow cells reported by Chervenick et al. (1968).
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Table 2. Frequency of HPP-CFC/1 3 103 CD341 Cells Plated
Cell Source CD34hi CD34lo CD34neg
Day 9 YS 266.7 6 17.2a 108.7 6 27.6b 1.7 6 0.5
Day 10 YS 155.3 6 33.7a 112.0 6 36.0b 1.9 6 1.3
Day 11 YS 59.3 6 32.9a 59.3 6 26.0b 7.7 6 3.8
Day 10 FL nac 12.3 6 4.3b 5.9 6 1.2
Day 11 FL na 43.3 6 17.9b 4.5 6 2.5
Day 12 FL na 52.7 6 43.0b 2.5 6 1.0
Adult BM na 116.0 6 8.7b 1.3 6 0.5
a Data presented as the mean 6 SD HPP-CFC colonies/1 3 103
CD341 cells plated in triplicate in 2±6 experiments. Colony counts
were significantly greater (P , 0.01) in cultures initiated with CD34hi
compared to CD34lo for day 9 yolk sac (YS) cells.
b Colony counts were significantly greater (P , 0.01) for cultures
initiated with CD34lo compared to CD34neg for day 9±11 yolk sac
cells.
c No data available (na) because CD34 analysis of cells in fetal liver
(FL) and adult bone marrow (BM) were CD34lo or CD34neg.
GATA-2 and c-Kit are highly expressed in primitive adult
bone marrow HSC, while EpoR was absent or detectable
at minimal levels (Orlic et al., 1995), these results support
the transplantation and clonogenic assays that indi-
cated that CD34 selection enriches for a more primitive
population of yolk sac cells including HSC.
Figure 3. Analysis of Growth Factor Receptor and Transcription
Clonogenic Analysis of CD341 Cells at DifferentFactor mRNA Expression in Adult Bone Marrow and Yolk Sac Cell
Populations Stages of Murine Ontogeny
Reverse transcriptase±PCR analysis of total cellular RNA from un- Hematopoietic cells from yolk sac, fetal liver, and adult
fractionated bone marrow, unfractionated yolk sac, and Lin2CD341 bone marrow were analyzed for CD34 expression, iso-
and Lin2CD342 day 9 yolk sac cells. Data from two representative lated, and plated in semisolid agar or methylcellulose
experiments are depicted in (a) and (b). All gene products listed to assay for the presence of high proliferative potential-
were analyzed on two occasions. b2-m mRNA served as a control
colony forming cells and hematopoietic progenitor cells,in each experiment for uniform loading.
respectively. The frequency of HPP-CFC was highest in
cultures containing CD34hi day 9 yolk sac cells (Table
2). At each stage of ontogeny, HPP-CFC frequency wasminimal H2-Kb (1.4%) or Gr-1 (1.6%) and no (,0.5%)
CD4, CD8, or B220 expression was observed (data not significantly higher in cultures initiated with cells ex-
pressing CD34 than in cultures containing CD34neg he-shown).
matopoietic cells (Table 2). Likewise, the frequency of
multipotential and committed hematopoietic progenitorAnalysis of Growth Factor and Transcription Factor
mRNA Expression by CD34-Enriched cells was significantly higher in cultures initiated with
CD34hi (in yolk sac) or CD34lo compared with CD34negDay 9 Yolk Sac Cells
Recent advances in HSC isolation and molecular biology cells at each stage of ontogeny (Table 3).
techniques have permitted analysis of mRNA expression
of growth factor receptors and transcription factors that Analysis of Long-Term Repopulating Ability of CD341
Cells at Different Stages of Murine Ontogenyare displayed at varying stages of HSC and progenitor
cell committment (Orlic et al., 1995). We compared the Transplantation of CD34hi and CD34lo yolk sac cells and
CD34lo fetal liver and adult bone marrow was performedlevel of mRNA expression of several growth factor re-
ceptors and transcription factors in populations of day using conditioned newborn mice as recipients. We have
previously demonstrated that unfractionated day 9±109 yolk sac cells that were enriched for CD341 cells with
the pattern of expression from day 9 yolk sac CD342 yolk sac cells readily engraft in sublethally myeloablated
newborn but not adult recipient mice (Yoder and Hiatt,cells, unfractionated day 9 yolk sac cells, and adult bone
marrow mononuclear cells (Figure 3). Day 9 CD341 yolk 1997; Yoder et al., 1997) while adult marrow cells engraft
in both conditioned newborn and adult recipients (Tray-sac cells expressed mRNA for all of the genes tested
(Figure 3). There was a 2.5:1 to 4:1 higher level of mRNA coff et al., 1996; Yoderet al., 1996). Day 9 yolk sac CD341
cell type Gpi-1 isoenzyme was minimally detectable atencoding c-Kit, GATA-1 (transcription factor), GATA-2
(transcription factor), AIC-2B (the common b subunit 2 months posttransplant in primary recipients; however,
the level of donor cell contribution increased in a dose-of the IL-3, IL-5, and GM-CSF receptors), and c-Myb
(transcription factor) in CD341 cells as compared to un- dependent fashion and thereafter remained consistent
from 6 to 12 months posttransplant in these recipientsfractionated day 9 yolk sac cells. In addition, the levels
of mRNA encoding c-Kit and GATA-2 were higher but (Table 4). The donor type contribution was evident in
erythroid, myeloid, and lymphoid lineages at 1 year post-EpoR (erythropoietin receptor) was lower in CD341 as
compared to CD342 day 9 yolk sac cells. Because transplant (Table 5). The number of primary recipients
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with demonstrable engraftment of 1000 or 2000 day 9
yolk sac CD341 cells was 10 of 12 and 12 of 12, respec-
tively, using the definition of a positive recipient as a
recipient with more than 4% donor type Gpi-1 at 6
months posttransplant (Harrison et al., 1993; Zhong et
al., 1996). CD341 day 10 yolk sac cells (1000) engrafted
in 10 of 10 recipients. CD342 cells isolated from day 9
or 10 yolk sacs did not engraft in conditioned newborn
recipient mice (0 of 18), although 12 of the primary recipi-
ent animals were observed to have . 4% donor type
Gpi-1 in circulating red and white blood cells at 2 and 3
months that was not present at 6 months posttransplant
(data not shown). Day 12 CD341 fetal liver cells (1000
cells) reconstituted conditioned newborns (6 of 6), as
did 1000 CD341 day 14 fetal liver cells (12 of 12), but
not 30,000 CD342 day 14 fetal liver cells (0 of 6). CD341
adult bone marrow cells (1000 cells) reconstituted 8 of
10 primary newborn recipients.
To determine if the transplanted day 9 yolk sac CD341
cells that engrafted in the primary recipients contained
HSC capable of self-renewal, we performed secondary
transplant experiments. Six months posttransplant, 6
primary recipients of CD341 day 9 yolk sac cells were
sacrificed and bone marrow cells isolated. Transplanta-
tion of marrow from each of the primary recipients into
3 lethally irradiated adult congenic recipients resulted
in reconstitution of peripheral blood erythroid, myeloid,
and lymphoid lineages in all 18 secondary recipient ani-
mals (Table 5). The level of donor CD341 yolk sac Gpi-1
chimerism observed in the primary recipients was reca-
pitulated in the secondary recipient animals (Table 5),
indicating that the yolk sac HSC were continuing to
actively contribute to hematopoiesis in the secondary
recipient animals. Similar results were obtained when 6
randomly selected primary recipients of day 10 CD341
yolk sac cells were sacrificed and bone marrow cells
were transplanted into secondary recipients (data not
shown). These results demonstrate that day 9 and 10
yolk sac CD341 cells contribute long-term to definitive
hematopoiesis in conditioned recipient mice.
Competitive Repopulation of Conditioned Newborn
Recipients with Day 9 CD341c-Kit1
Yolk Sac and P-Sp
Definitive HSC activity has been reported to arise before
colonization of the liver (28 somite stage) in the P-Sp and
not the yolk sac when using conditioned adult recipients
(Cumano et al., 1996; Medvinsky and Dzierzak, 1996).
However, we (Yoder et al., 1997) and others (Weissman
et al., 1978) have observed that yolk sac cells obtained
before colonization of the liver reconstitute definitive
hematopoiesis upon transplantation into newborn or
embryonic mice. In the present experiments, we isolated
an enriched population of day 9 HSC from the P-Sp and
yolk sac to compare repopulating ability of these cells.
Recently, c-Kit1CD341 HSC have been identified in the
AGM (derived from the P-Sp) at day 11 (Sanchez et al.,
1996). We hypothesized that the CD341c-Kit1 pheno-
type would enrich for HSC in both the day 9 yolk sac
and P-Sp upon transplantation of these cells into condi-
tioned newborn recipients, since day 9 CD341 yolk sac
T
ab
le
3.
F
re
q
ue
nc
y
o
f
H
em
at
o
p
o
ie
tic
P
ro
g
en
ito
r
C
el
ls
/1
3
10
3
C
D
34
1
C
el
ls
P
la
te
d
C
D
34
hi
C
D
34
lo
C
D
34
ne
g
C
el
l
S
o
ur
ce
G
M
-C
F
C
M
ix
-C
F
C
B
F
U
-E
G
M
-C
F
C
M
ix
-C
F
C
B
F
U
-E
G
M
-C
F
C
M
ix
-C
F
C
B
F
U
-E
D
ay
9
Y
S
42
.9
6
5.
9
a
65
.2
6
9.
4
a
22
.9
6
6.
0a
13
.5
6
5.
7b
12
.0
6
7.
0
b
16
.7
6
7.
4b
0.
9
6
0.
3
0.
7
6
0.
5
0.
2
6
0.
2
D
ay
10
Y
S
37
.0
6
8.
3
a
55
.3
6
7.
2
a
30
.1
6
7.
5a
14
.1
6
4.
7b
15
.3
6
9.
2
b
16
.3
6
7.
3b
1.
2
6
0.
3
1.
3
6
0.
3
1.
2
6
0.
2
D
ay
11
Y
S
48
.1
6
8.
4
a
48
.8
6
11
.0
a
21
.9
6
10
.9
a
13
.7
6
2.
5b
13
.5
6
4.
8
b
12
.8
6
1.
4b
1.
1
6
0.
4
0.
9
6
0.
2
0.
9
6
0.
3
D
ay
10
F
L
na
c
na
na
7.
3
6
1.
0b
2.
7
6
0.
6
b
4.
3
6
1.
2b
0.
5
6
0.
1
0.
9
6
0.
2
0.
5
6
0.
1
D
ay
11
F
L
na
na
na
5.
0
6
0.
5b
2.
8
6
0.
6
b
1.
9
6
0.
9b
0.
7
6
0.
2
0.
7
6
0.
5
0.
4
6
0.
2
D
ay
12
F
L
na
na
na
44
.0
6
16
.9
b
20
.7
6
20
.5
b
26
.7
6
4.
5b
0.
7
6
0.
3
0.
6
6
0.
2
0.
2
6
0.
2
A
d
ul
t
B
M
na
na
na
12
6.
7
6
40
.4
b
16
.8
6
11
.6
b
36
.7
6
5.
8b
0.
4
6
0.
2
0.
4
6
0.
4
0.
3
6
0.
2
a
T
he
m
ea
n
6
S
D
co
lo
ny
co
un
ts
o
f
g
ra
nu
lo
cy
te
m
ac
ro
p
ha
g
e-
co
lo
ny
fo
rm
in
g
ce
lls
(G
M
-C
F
C
),
m
ul
til
in
ea
g
e
co
lo
ny
fo
rm
in
g
ce
lls
(m
ix
-C
F
C
),
an
d
b
ur
st
fo
rm
in
g
un
it-
er
yt
hr
o
id
co
lo
ny
fo
rm
in
g
ce
lls
(B
F
U
-E
)
w
er
e
si
g
ni
fic
an
tly
g
re
at
er
(P
,
0.
01
)
in
cu
ltu
re
,i
ni
tia
te
d
w
ith
C
D
34
hi
as
co
m
p
ar
ed
to
C
D
34
lo
an
d
C
D
34
ne
g
ce
lls
fo
r
d
ay
9±
11
yo
lk
sa
c
ce
lls
.
R
es
ul
ts
ar
e
fr
o
m
3
ex
p
er
im
en
ts
.
b
C
o
lo
ny
co
un
ts
o
f
G
M
-C
F
C
,
m
ix
-C
F
C
,
an
d
B
F
U
-E
w
er
e
g
re
at
er
(P
,
0.
01
)
in
cu
ltu
re
s
in
iti
at
ed
w
ith
C
D
34
lo
th
an
C
34
ne
g
ce
lls
fo
r
al
ly
o
lk
sa
c,
fe
ta
ll
iv
er
ce
lls
.
c
N
o
d
at
a
av
ai
la
b
le
(n
a)
b
ec
au
se
C
D
34
an
al
ys
is
o
f
ce
lls
in
fe
ta
ll
iv
er
(F
L)
an
d
ad
ul
t
b
o
ne
m
ar
ro
w
(B
M
)
w
er
e
C
D
34
lo
o
r
C
D
34
ne
g .
cells reconstituted these hosts long-term and both day
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Table 4. Percent of Primary Recipient Animal Peripheral Red Blood Cells with Donor Type Day 9 CD341 Cell Gpi-1 at Varying Times
Posttransplant
% Donor Type Gpi-1 in Red Blood Cells
CD341 Cell Number 2 months 4 months 6 months 12 months
1000 2 6 4 10 6 9 12 6 9 13 6 10
2000 2 6 2 18 6 9 21 6 12 27 6 8
Red blood cells were isolated as a pellet from the peripheral blood of primary recipient animals at varying intervals posttransplant. The red
blood cells were lysed and the percent donor and host Gpi-1 isoenzymes were determined.
Results are presented as the mean 6 SD % Gpi-1 from 22 animals.
9 yolk sac and P-Sp cells express c-Kit (Ogawa et al., by the percentage of CD341c-Kit1 isolated (Figures 2
and 4), the estimated pool of CD341c-Kit1 cells isgreater1993; Marcos et al., 1997). The percentage of P-Sp cells
expressing CD34 was less than that observed for the in the day 9 yolk sac (7350 cells) than in the day 9 P-Sp
(198 cells). These results demonstrate that definitiveday 9 yolk sac (Figures 1 and 4). In addition, the overall
level of CD34 expression by P-Sp cells was lower with HSC are present at day 9 in CD341c-Kit1 cells present
in the yolk sac and P-Sp but there are 37-fold more ofnone of the highly expressing CD341 cells (present in
the day 9 yolk sac) present in this site (Figures 1 and 4). these cells in the yolk sac than in the P-Sp.
Furthermore, the percentage of c-Kit-expressing CD341
cells in the day 9 P-Sp was lower than that observed Discussion
in the day 9 yolk sac (Figures 2 and 4). Nevertheless,
CD341c-Kit1 day 9 yolk sac and P-Sp contained equally CD34 is expressed on human hematopoietic stem and
progenitor cells, small-vessel endothelium, and embry-high concentrations of multipotent and committed pro-
genitor cells and HPP-CFC (Table 6). CD341c-Kit2 cells onic fibroblasts (Krause et al., 1996). In human bone
marrow, CD34 is only expressed on approximately 1.5%from the day 9 yolk sac and P-Sp were not clonogenic
(data not shown). To permit us toquantitate repopulating of bone marrow mononuclear cells; however, this frac-
tion is enriched in transplantable HSC, and therefore,ability of theseenriched HSC populations, we coinjected
50, 100, or 200 CD341c-Kit1 yolk sac or P-Sp cells with CD34 enrichment protocols are widely used to obtain
material for clinical bone marrow transplants (Krause et50,000 day 12 congenic fetal liver cells as competitors.
Four months posttransplant, multilineage reconstitution al., 1996). In contrast, CD34 may or may not serve as a
marker of adult murine bone marrow HSC (Krause et al.,was observed in similar numbers of primary recipient
animals transplanted with either 100 or 200 CD341 1994; Morel et al., 1996; Osawa et al., 1996). Because
the published studies (Krause et al., 1994; Morel et al.,c-Kit1 day 9 yolk sac or P-Sp cells (Table 7, Figure 5).
None of the recipients transplanted with 50 CD341 1996; Osawa et al., 1996) examining CD34 expression
on adult murine bone marrow HSC have differed in typec-Kit1 yolk sac or P-Sp cells competed well enough with
the day 12 fetal liver cells to be detectable (Table 7). of antibody used (monoclonal versus polyclonal), donor
mouse strain, method of recipient myeloablation, andThe level of reconstitution contributed by the CD341
c-Kit1 yolk sac or P-Sp cells in those animals where the use of single or multiple cell surface markers for HSC
identification, it remains unclear whether CD34 aloneCD341c-Kit1 competed with the fresh day 12 fetal liver
cells was similar.Calculation of repopulating unit activity can serve as a reagent to identify bone marrow HSC.
Nevertheless, mutant mice made deficient in CD34 ex-indicates that at 4 months posttransplant the day 9 yolk
sac cell (200 cells) RU of 0.95 was similar to the 1.17 pression via targeted disruption of thenormal gene dem-
onstrate deficiencies in embryonic yolk sac, fetal liver,RU for day 9 P-Sp (200 cells). These results indicate
that 200 day 9 CD341c-Kit1 yolk sac and P-Sp cells and adult bone marrow hematopoietic progenitor cell
proliferation in vivo and in vitro in response to recombi-contain HSC that display 0.95 and 1.17 times more re-
populating ability than 1 3 104 fresh day 12 fetal liver nant cytokine stimulation (Cheng et al., 1996). Taken
together, these studies suggest that while CD34 is notcells (Harrison et al., 1993). If the total number of cells
isolated from the yolksac and P-Sp (Table 1) ismultiplied essential for hematopoiesis, this sialomucin plays an
Table 5. Percent Donor Type Gpi Present in Peripheral Blood Lymphocytes, Granulocytes, and Red Blood Cells of Primary (12 Months
Posttransplant) and Secondary Recipients (6 Months Posttransplant)
% Donor Type Gpi-1 in Primary Recipients % Donor Type Gpi-1 in Secondary Recipients
CD341 Cell Number B cell T cell Granulocyte Erythroid B cell T cell Granulocyte Erythroid
1000 11 6 6 10 6 6 11 6 8 13 6 10 10 6 7 8 6 4 11 6 5 13 6 6
2000 17 6 8 18 6 7 23 6 11 27 6 8 17 6 8 16 6 6 19 6 10 25 6 8
Data presented represents the mean 6 SD percent donor Gpi-1 observed in 6 randomly selected primary recipients of 1000 or 2000 CD341
day 9 yolk sac cells at 1 year posttransplant. Peripheral blood was drawn and individual cell lineages were isolated and analyzed for percent
donor type Gpi-1 isoenzyme. The mean 6 SD percent donor type Gpi-1 isoenzyme value for individual cell lineages are also depicted for
secondary recipients (6 representative animals of 18) 6 months after receipt of bone marrow cells from primary recipients of 1000 or 2000
CD341 day 9 yolk sac cells.
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Figure 5. Percent Donor Type Gpi-1 Isoenzyme Present in Periph-
eral Blood Cells of Primary Recipients of CD341c-Kit1 Day 9 Yolk
Sac and P-Sp Cell Transplants
Analysis of peripheral blood of primary recipient mice reconstituted
with 200 CD341c-Kit1 day 9 yolk sac or P-Sp cells. Donor cells were
derived from C57BL/6J (C57) animals expressing Gpi-1b, and the
Figure 4. Analysis of CD34 and c-Kit Expression on Day 9 P-Sp recipient congenic B6. mice express Gpi-1a. Though each strain
Cells expresses multiple Gpi-1 isoenzymes, Gpi-1a recipients do not ex-
(A) Isotype control±labeled day 9 P-Sp cells are depicted in the open press Gpi-1b. Donorcell±derived Gpi-1b is present in B and T lympho-
histogram, and the CD34-labeled cells in the shaded histogram. The cytes and granulocytes (G) of three primary recipients of yolk sac
percentage of cells indicated are those considered positive. cells and four primary recipients of P-Sp cells.
(B) The FACS dot plot reflects the percentages of day 9 P-Sp cells
that were labeled with CD34 and/or c-Kit antibodies.
et al., 1996). In further contrast to day 9 CD341 yolk sac
cells, adult marrow HSC express H2-k antigens (Ogataimportant role in murine embryonic and adult hemato-
poiesis. et al., 1995). These results support a growing body of
evidence that the expression of cell surface antigensBecause CD34 expression has been demonstrated on
hematopoietic and endothelial cells of murine yolk sac changes on HSC during murine ontogeny and that in
vivo assays of HSC function are required to confirm HSCblood islands (Fennie et al., 1995; Young et al., 1995),
we investigated the level of CD34 expression on hema- identity (Morrison et al., 1995b).
Our observation that CD341c-Kit1 cells from the daytopoietic cells at several early stages of murine ontog-
eny. We now report that CD34 was expressed by a 9 yolk sac and P-Sp reconstituted definitive hematopoi-
esis in conditioned newborn mice constitutes the firstsubset of day 9±11 yolk sac hematopoietic cells. At later
stages of murine ontogeny, fewer CD341 hematopoietic determination that such a defined population of HSC
exists in the day 9 murine embryo and yolk sac. Severalcells with diminished levels of CD34 expression were
observed. However, hematopoietic cell proliferation groups have recently described the patterns of cell sur-
face antigen expression displayed by extraembryonicwithin each successive hematopoietic compartment (to-
tal cells in yolk sac , fetal liver , bone marrow) resulted (yolk sac) and intraembryonic (P-Sp, AGM, and fetal
liver) hematopoietic cells during murine ontogeny (San-in increases in the total number of CD341 cells present
in the primary sites of differentiated blood cell produc- chez et al., 1996; Marcos et al., 1997). However, the
earliest in vivo repopulating ability previously reportedtion as ontogeny proceeded. Isolation and plating of
CD341 yolk sac, fetal liver, and bone marrow cells in for CD341c-Kit1 cells was identified in cells isolated
from the day 11 AGM (Sanchez et al., 1996). The pres-clonogenic assays demonstrated that CD341 cells were
enriched at each stage of ontogeny for hematopoietic ence of HSC activity in a defined population in the day
11 AGM was consistent with the report by Medvinskyprogenitor cells compared to CD342 cells. Furthermore,
transplantation of CD341, but not CD342, day 9 or 10 and Dzierzak (1996) that definitive HSC first appear in
the day 10 AGM. How can we reconcile these observa-yolk sac cells into conditioned newborn recipients re-
sulted in sustained donor cell contributions to multiple tions of Sanchez et al. (1996) and Medvinsky and Dzier-
zak (1996) with our current evidence that both day 9 yolkblood cell lineages for up to 1 year in primary recipients
and 6 months in secondary recipient animals. Thus, sac and P-Sp contain hematopoietic cells with definitive
repopulating ability? The seminal variable distinguishingCD34 serves as an important reagent for the isolation
of hematopoietic stem and progenitor cells from the the previous observations with the current results is that
we have transplanted enriched populations of yolk sacyolk sac as early as day 9 (15±20 somite stage).
A significant proportion of day 9 yolk sac cells coex- and P-Sp cells into conditioned newborn recipient mice,
whereas Medvinsky and Dzierzak (1996) and Sanchezpressed CD34 and c-Kit, CD24, CD38, CD44, Mac-1,
and AA4.1; however, little or no coexpression of CD34 et al. (1996) transplanted embryonic and fetal cells into
conditioned adult recipient mice. The failure of embry-and H2-k, Gr-1, CD4, CD8, B220, and Sca-1 was ob-
served. This pattern of cell surface marker expression onic day , 10 HSC from the yolk sac and P-Sp to engraft
in adult recipients may be related to the failure of theseis similar to that described previously for day 9±11 yolk
sac cells (Huang and Auerbach, 1993; Marcos et al., early HSC to express the appropriate homing molecules
and/or hematopoietic growth factor receptors that per-1997) but is distinctly different from fetal liver and adult
HSC. Fetal liver HSC are known to express c-Kit, CD38, mit engraftment and expansion in the bone marrow he-
matopoietic environment of the adult host. It is alsoMac-1, and AA4.1 but also express Sca-1, a marker not
present on day 9 yolk sac CD341 cells (Ziegler et al., possible that these embryonic HSC may home to the
adult marrow cavity but do not survive because of the1994; Morrison et al., 1995a; Randall et al., 1996; San-
chez et al., 1996). Adult marrow HSC also express c-Kit, failure of the adult microenvironment to produce distinct
embryonic HSC growth factors. Nevertheless, our ob-CD38, and Sca-1 but do not normally express Mac-1 or
AA4.1 (Orlic et al., 1993; Morrison et al., 1995a; Randall servations suggest that day 9 yolk sac and P-Sp
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Table 6. Frequency of HPP-CFC and Hematopoietic Progenitor Cells/1 3 103 CD341 c-Kit1
HPP-CFC GM-CFC Mix-CFC BFU-E
Day 9.0 yolk sac 316.7 6 57.7 47.8 6 15.2 7.8 6 5.6 8.3 6 0.9
Day 9.0 P-Sp 286.7 6 80.2 38.7 6 13.6 6.7 6 3.1 5.7 6 1.2
FACS enriched day 9 yolk sac and P-Sp cells were plated in triplicate cultures for enumeration of clonogenic cells in three experiments. No
significant difference in colony cell numbers was detectable.
CD341c-Kit1 cells do possess the required homing mol- (Dzierzak and Medvinsky, 1995; Dieterlen-Lievre et al.,
1997). Whether these two pools are directly related orecules and/or growth factor receptors that permit en-
graftment and expansion of transplanted embryonic arise independently has not been clarified (Dzierzak and
Medvinsky, 1995). The results presented herein castHSC in the conditioned newborn mice. Further studies
to examine the site of yolk sac and P-Sp homing in the some doubt on the existence of a two-pool system of
HSC development for several reasons: (1) multipotentconditioned newborn mice and to investigate the in vivo
growth factor requirements for embryonic HSC would progenitor and HPP-CFC comprised of mature blood
cells are enriched in pools of CD341c-Kit1 cells that arebe instructive.
Several models describing the ontogeny of HSC activ- simultaneously present in the day 9 yolk sac and P-Sp;
(2) definitive HSC activity can be detected concomitantlyity in the murine embryo have recently been proposed
(Dzierzak and Medvinsky, 1995; Medvinsky and Dzier- in the yolk sac and P-Sp at a preliver stage of develop-
ment; and (3) the large number of CD341c-Kit1 cellszak, 1996; Peault, 1996; Dieterlen-Lievre et al., 1997;
Marcos et al., 1997), and in general, these models restrict (including HSC) in the day 9 yolk sac is unlikely to be
derived from the smaller pool (37-fold less CD341c-Kit1the origin of liver-seeding, definitive HSC to the embry-
onic AGM region. These models are valid if one defines cells) of day 9 P-Sp cells. Formal proof that the yolk sac
pool of HSC arises autonomously of the P-Sp awaitsas a minimum requirement that HSC function as cells
that reconstitute the lymphohematopoietic system of an analysis of transplantation experiments using donor yolk
sac and P-Sp cells isolated prior to the onset of theadult animal upon transplantation of the candidate cells
into an adult host (Orlic and Bodine, 1994). However, if systemic circulation.
In conclusion, we have demonstrated that the day 9one more broadly defines a HSC as a cell that reconsti-
tutes the definitive lymphohematopoietic system of a yolk sac contains CD341 HSC that contribute to sus-
tained multilineage hematopoiesis in conditioned new-recipient animal following transplantation, to accomo-
date our observations, then a more robust model of born hosts. Comparison of the repopulating ability of
day 9 CD341c-Kit1 cells isolated from the yolk sac andmurine HSC development is required. We propose a
model of HSC development that identifies the yolk sac, P-Sp demonstrates similar repopulating ability in condi-
tioned newborn recipient mice. The observation thatas well as the P-Sp and later the AGM, as the most likely
sites of origin of HSC that migrate to the fetal liver and HSC contributing to definitive hematopoiesis are con-
comitantly present in the day 9 yolk sac and P-Sp at ainitiate the definitive hematopoietic production of ma-
ture blood cells. preliver stage of development calls for a reassessment
of the role of yolk sac HSC in the colonization of theA question that remains unanswered is whether the
HSC activity identified in the day 9 yolk sac and P-Sp liver during murine development. Further studies to test
whether HSC arise autonomously in the precirculationis derived from a common HSC precursor or arises au-
tonomously in each site. It has been postulated that yolk sac and P-Sp are warranted.
there are two pools of HSC in the murine embryo, a
primitive pool that gives rise to committed primitive pro- Experimental Procedures
genitor cells in the yolk sac that may or may not seed
Cell Preparationthe liver in a first wave of short-lived hematopoietic
Embryos were obtained and staged by somite counting as pre-activity and a definitive pool originating in the AGM that
viously described (Yoder and Hiatt, 1997). Dissected yolk sacs were
seeds the fetal liver, bone marrow, and perhaps the yolk incubated with 0.1% collagenase (Sigma, St. Louis, MO) in 20%
sac with multipotent progenitors and HSC that become fetal calf serum (FCS) for 30 minutes at 378C, and dispersed yolk sac
cells weredrawn through a 23G needle, deposited into a polystyrenethe long-lived contributors to definitive hematopoiesis
Table 7. Percent Donor Type Gpi-1 Isoenzyme in Primary Recipients of CD341 c-Kit1 Day 9 Yolk Sac and P-Sp Cell Transplants
Cells per Recipient Positive Recipients B Cell T Cell Granulocyte Erythroid
50 YS 0 of 5 0 0 0 0
100 YS 3 of 8 12 6 6 10 6 3 10 6 6 12 6 6
200 YS 3 of 6 15 6 6 14 6 4 18 6 7 18 6 8
50 P-Sp 0 of 6 0 0 0 0
100 P-Sp 3 of 6 9 6 6 8 6 3 15 6 3 14 6 5
200 P-Sp 4 of 6 18 6 6 14 6 7 22 6 6 24 6 6
Conditioned newborn mice were transplanted with varying numbers of sorted cells (plus fresh day 12 congenic fetal liver competitor cells)
from day 9 pooled yolk sacs (YS) or P-Sp. Four months posttransplant, peripheral blood was drawn and individual cell lineages isolated and
analyzed for the percent donor type Gpi-1 isoenzyme (mean 6 SD) in B and T lymphocytes, granulocytes, and erythroid cells.
Immunity
342
tube, and pelleted at 500 g for 10 minutes. A single-cell suspension cycler (Perkin Elmer Cetus, Norwalk, CT) for 35 cycles, and the
amplified cDNA reaction product was resolved by electrophoresisof fetal liver cells was isolated from pregnant dams on days 10±14
via mincing of the tissue with a fine forceps in Hanks balanced salt in a 5% polyacrylamide gel.
Phosphor screens (Molecular Dynamics, Sunnyvale, CA) were ex-solution (HBSS) with 10% FCS, trituration with a 5 ml pipette, and
drawing the cells through a 23G needle. Bone marrow mononuclear posed to the radioactive filters for 1 hour, and the bands formed by
the decay of 32P-CTP-labeled cDNAwere quantified with a Molecularcells were obtained from adult mice using standard methods (Yoder
et al., 1993). P-Sp was isolated using the method of Godin et al. Dynamics Densitometer System (Sunnyvale, CA). b2-m mRNA val-
ues were used as internal standards to quantitate mRNA expression(1995) with a modification that the tissue was incubated in 0.1%
collagenase in 20% FCS and HBSS for 30 minutes at 378C before for each cytokine receptor and transcription factor. All calculations
were done using the following formula: (test gene mRNA in a yolkbeing drawn through a 23G needle. The cell suspensions were
counted and viability tested via Trypan blue exclusion criteria. The sac or bone marrow sample/b2-m mRNA in the same yolk sac or
marrow sample) 3 100 5 relative % test gene mRNA.care and use of animals in these studies was approved by the
Indiana University School of Medicine Institutional Animal Care and
Use Committee. Transplantation Assay
Timed-pregnant B6.Hbbd/Hbbd, Gpi-1a/Gpi-1a (B6.Hbbd, Gpi-1a)
dams were injected on days 17 and 18 with 15 mg/g busulfan (20CD34 Cell Analysis and Cell Sorting
Cell suspensions were incubated on ice in the presence of rat anti- mg/ml in 1% carboxymethylcellulose; Sigma) to lethally condition
(80% LD at 90 days) their pups at the time of delivery (Yoder et al.,mouse CD16/CD32 (1 mg/106 cells; Pharmingen, San Diego, CA) to
block Fc receptor function and diminish background nonspecific cell 1996). C57BL/6J CD341 (1,000±2,000) orCD342 (10,000±30,000) yolk
sac cells were suspended in 25 mL HBSS and drawn into a 100 mLlabeling. Cells were incubated with rat anti-mouse biotin-conjugated
CD34 (RAM34 clone; Pharmingen) on ice. Subsequently, cells were sterile glass syringe adapted with an injection guide (Hamilton,
Reno, Nevada). The cell suspension (with 50,000 day 12 congenicwashed, pelleted, and resuspended with streptaviden-conjugated
phycoerythrin (PE) for a final incubation. Labeled cells were pelleted fetal liver cells) was directly injected into the fetal liverof therecipient
(equivalent to intravenous route of injection; Yoder et al., 1997).and resuspended in HBSS with 5% FCS, and specific populations
of cells isolated using a FACStar1 instrument (Becton Dickinson,San Peripheral blood of all recipient animals was sampled from 1 to 12
months posttransplant for assay of donor type Gpi-1 isoenzymeJose, CA) and appropriate isotype antibody controls as previously
described (Yoder and Hiatt, 1997). In some experiments, cells were chimerism.
Marrow low-density mononuclear cells (LDBM) were recoveredincubated with fluorescein isothiocyanate (FITC)±conjugated CD4,
CD8, CD24, CD38, CD44, Gr-1, Sca-1, Mac-1, TER119, H-2Kb, c-Kit from primary recipients 6 months posttransplant, and 3 3 106 cells
from each primary recipient were intravenously injected into three(all Pharmingen), and AA4.1 (identified with a FITC-conjugated
mouse anti-rat IgG2b antibody) or appropriate isotype control anti- secondary recipient B6.Hbbd,Gpi-1a adult animals that had been
conditioned with total body irradiation (11 Gy g irradiation adminis-bodies and CD34. In other experiments, day 9 yolk sac and P-Sp
were resolved into CD341c-Kit1 populations and isolated for pro- tered at 96 cGy/min in two doses divided by 4 hours using a 137Cs
irradiator [Nordion, Kanata, Canada]). In other experiments, primarygenitor cell analysis and transplantation assays.
newborn recipients were transplanted with CD341 or CD342 day 12
or 14 fetal liver or adult bone marrow cells (with 50,000 day 12 fetalHPP-CFC Assay
liver competitor cells). Finally, CD341c-Kit1 day 9 yolk sac and P-SpDouble-layer agar cultures were prepared as previously described
cells were transplanted (with 50,000 day 12 congenic fetal liver(Yoder et al., 1995). Recombinant hematopoietic growth factors in-
competitor cells) into conditioned newborn recipients. Recipientcluding human macrophage colony stimulating factor-1 (M-CSF,
animals were sequentially bled and peripheral blood cells isolated1600 U, gift of Genetics Institute, Boston, MA), murine interleukin-3
for determination of donor cell reconstitution of peripheral blood(IL-3, 200 U) and murine interleukin-1a (IL-1a, 500 U, Genzyme,
lineages. Repopulating unit (RU) activity of the yolk sac and P-SpCambridge, MA), and rat stem cell factor (SCF, 100 ng,gift of Amgen,
donor cells was calculated according to the formula of Harrison etThousand Oaks, CA) were used in combination in a final volume of
al. (1993). In this study, 1 RU is equal to the repopulating ability of1.5 ml. Sorted yolk sac, fetal liver, or bone marrow cells were plated
1 3 104 fresh day 12 fetal liver cells infused into a conditioned(500 cells/dish) in triplicate and incubated in a 5% O2, 10% CO2,
newborn (cell number that reconstitutes 100% of conditioned new-and 85% N2 humidifiedenvironment. On day14 of culture,colonies .
borns; not shown).0.5 cm were scored as HPP-CFC.
Peripheral Blood Cell Isolation and GlucoseHematopoietic Progenitor Assay
Phosphate Isomerase-1 AssaySorted cells were plated (500±1000 cells/dish) in triplicate 0.9%
Buffy coat mononuclear cells and red cell pellets were isolated andmethylcellulose cultures as previously described (Yoder et al., 1993).
incubated with the rat monoclonal antibodies Gr-1, B220, or CD4/In addition to using rSCF, hM-CSF, mIL-3, and mIL-1a, 2U human
CD8 (all Pharmingen, San Diego, CA) for isolation of granulocytes,recombinant erythropoietin (Epo) was added. Colony types were
B lymphocytes, and T lymphocytes, respectively. Cell populationsscored both by morphological appearance and by plucking and
were obtained by FACS and frozen at 2808C for Gpi-1 analysis.Wright-Giemsa staining of colonies applied to glass slides for deter-
Isolated red blood cells, B and T lymphocytes, and granulocytesmination of the type of matureblood cells present. In all experiments,
were lysed by freeze-thawing in distilled water. The cell lysatesstatistically significant differences were determined using Student's
were applied to Titan III Zip Zone cellulose acetate plates (Helena,t test with a level of significance set at P , 0.01, and all data are
Beaumont, TX)using a Super Z 0.5 mL 8-well applicator (Helena). Therepresented as mean 6 SD.
loadedgels wererun for 30minutes in an electrophoresis chamber at
300 V. The Gpi-1 isoenzymes were detected as recently describedReverse Transcriptase±Polymerase Chain Reaction (RT±PCR)
(Yoder and Hiatt, 1997). Stained gels were scanned with a RepTotal cellular RNA was isolated from unfractionated bone marrow
clinical densitometer (Helena) for quantitation.and yolk sac, and from TER119-depleted (Lin2) CD341 and CD342
day 9 yolk sac cells using RNAzol B (Tel-Test, Inc., Friendswood,
AcknowledgmentsTX). First-strand cDNA was prepared by reverse transcription ac-
cording to the manufacturer's instructions (Perkin Elmer Cetus, Nor-
We thank Jim Palis, Andrew Roberts, D. Wade Clapp, and Reubenwalk, CT) using a 20 ml reaction volume. Using our previously pub-
Kapur for critical reading of the manuscript. This work was sup-lished protocol (Orlic et al., 1995, 1996), we estimated the
ported in part by research Grant # 6-FY96-1057 from the March ofconcentration of RNA in each sample by a limiting dilution assay
Dimes Birth Defects Foundation. We thank Pat Fox for manuscriptusing aliquots of 1.0 mL, 0.1 mL, and 0.01 mL in reaction mixtures
preparation.containing primers for b2-microglobulin (b2-m), a constitutively ex-
pressed gene. The PCR was performed at 948C for 1 minute, 588C
or 628C for 1 minute, and 728C for 2 minutes using a DNA thermal Received June 5, 1997.
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